Sinovac Gets Drug Certificate From China for Split Flu Vaccine

Sinovac Biotech has received the new drug certificate from the Chinese State Food and Drug Administration (SFDA) for its Split Influenza vaccine.

The SFDA approval comes as the company is nearing completion of its new production line in Beijing. The official approval marks a significant milestone in the growth of Sinovac's portfolio of low-cost, high quality inactivated vaccines.

The company's Split Flu vaccine, which is safe for use in children as well as the elderly, is the third Sinovac vaccine for which the SFDA has granted a new drug certificate. The first two Sinovac products, Healive, a hepatitis A vaccine, and Bilive, a combined vaccine for hepatitis A and B, have helped establish the company as an emerging leader in the Chinese biotechnology sector.